Alan R. Shaw PhD

Alan R. Shaw, Ph.D., is Chairman and Chief Scientific Officer at VaxInnate Corporation where he is responsible for the scientific and medical conduct of the company’s efforts to develop new vaccines incorporating pathogen-associated molecular patterns. He joined VaxInnate in 2005 following a 15year career at Merck Research Laboratories where he was responsible for R&D leading to the licensure of Varivax®, ProQuad®, Zostavax®, RotaTeq®, and Gardasil®.

Prior to joining Merck, Dr. Shaw was a Senior Program Executive at Biogen S.A in Geneva, Switzerland where he led projects on hepatitis B vaccines, malaria vaccines, cytokines, and their inhibitors, and cell trafficking. Dr. Shaw was the Chairman of the International Federation of Pharmaceutical Manufacturers’ Association Biologicals Committee and has extensive experience in national and international vaccine development and policy matters.

Dr. Shaw received his Ph.D. in Molecular Biology and Biochemistry from the Medical College of Ohio and was a post-doctoral fellow at the International Institute for Cellular Pathology in Brussels and at the Rockefeller University in New York. Dr. Shaw’s expertise is in the areas of virology, molecular biology, immunology, and protein chemistry. He has served as an adjunct faculty member at Temple University in Philadelphia. He is currently a member of the NIH Board of Scientific Counselors.